All research
Human randomized trial / 2023
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al.
Study overview
This placebo-controlled phase 2 trial followed 338 adults for 48 weeks. The investigational receptor agonist produced weight reduction across treatment groups; gastrointestinal events and increases in heart rate were reported.
Results are specific to the study. This is an editorial summary, not personal treatment advice.
Study limitations
A phase 2 result does not establish long-term safety, outcomes in excluded groups, or regulatory approval. This record describes the 2023 publication, not a current regulatory-status assessment.
About this summary
This summary uses the cited abstract and bibliographic record. Read the original methods and results for the full context.